Dakshidin Corporation, Inc. (DKSC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Dakshidin Corporation, Inc. (DKSC) trades at $0.00 with AI Score 50/100 (Grade B). Dakshidin Corporation, Inc. operates in the CBD/cannabis-based medical product sector, focusing on cultivation and online sales. Market cap: $1.77M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for DKSC: DKSC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DKSC against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
DKSC: the 1 perspectives are evenly split.
How is this calculated? →Dakshidin Corporation, Inc. (DKSC) Healthcare & Pipeline Overview
Dakshidin Corporation, Inc. is a CBD/cannabis-based medical product company involved in cultivation, online sales, and distribution channel management. Operating in the specialty and generic drug manufacturing industry, the company focuses on retail, reselling, and direct sales markets, with its headquarters in Miami and offices in Las Vegas.
What Is the Investment Thesis for DKSC?
Dakshidin Corporation, Inc. operates in the high-growth CBD/cannabis market, but its financial viability is questionable given its negative P/E ratio of -145.24. The company's success hinges on its ability to scale its cultivation operations, expand its online sales portal, and effectively manage its distribution channels. The company's beta of -1.23 suggests a negative correlation with the market, which could be seen as both a risk and an opportunity. Key value drivers include regulatory changes favoring cannabis use, expansion of product lines, and strategic partnerships. However, the company faces risks related to competition, regulatory uncertainty, and market volatility. Investors should closely monitor Dakshidin's revenue growth, cost management, and cash flow generation to assess its long-term potential.
Based on FMP financials and quantitative analysis
DKSC Key Highlights
- Dakshidin Corporation, Inc. operates in the CBD/cannabis-based medical product sector.
- The company's P/E ratio is -145.24, indicating it is not currently profitable.
- Dakshidin's beta is -1.23, suggesting a negative correlation with the market.
- The company cultivates cannabis and operates an online sales portal for CBD products.
- Dakshidin manages distribution channel programs in retail, reselling, and direct sales markets.
Who Are DKSC's Competitors?
DKSC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DKSC's Key Strengths?
- Established presence in the CBD/cannabis market.
- Online sales portal for direct-to-consumer sales.
- Management of diverse distribution channels.
- Cultivation capabilities for supply chain control.
What Are DKSC's Weaknesses?
- Negative P/E ratio indicating lack of profitability.
- Limited financial resources compared to larger competitors.
- Dependence on evolving regulatory environment.
- Unknown Disclosure Status on the OTC market.
What Could Drive DKSC Stock Higher?
- Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
- Expansion of the company's online sales portal and marketing efforts to drive revenue growth.
- Strategic partnerships with established companies to expand market reach and distribution channels.
What Are the Key Risks for DKSC?
- Financial-distress signal — its Altman Z-Score of -4.00 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from other CBD/cannabis companies could erode market share and profitability.
- Evolving regulations and legal restrictions surrounding cannabis could negatively impact the company's operations.
- Fluctuations in cannabis prices and demand could affect revenue and profitability.
- Negative publicity and consumer perception of cannabis could harm the company's brand and reputation.
What Are the Growth Opportunities for DKSC?
- Expansion of Product Lines: Dakshidin can expand its product lines to include a wider range of CBD and cannabis-based medical products, such as edibles, topicals, and concentrates. The global cannabis market is projected to reach $47 billion by 2025, offering significant growth potential for companies with diverse product offerings. This expansion could be achieved through internal research and development or strategic acquisitions of companies with complementary product portfolios. Timeline: 1-2 years.
- Strategic Partnerships: Dakshidin can form strategic partnerships with established pharmaceutical companies, retailers, and distributors to expand its market reach and access new customer segments. Collaborations with pharmaceutical companies could facilitate the development and commercialization of cannabis-based therapies, while partnerships with retailers and distributors could enhance the company's distribution network. The timeline for establishing strategic partnerships is ongoing.
- Geographic Expansion: Dakshidin can expand its operations into new geographic markets, both domestically and internationally, as regulations surrounding cannabis and CBD evolve. The European cannabis market is expected to experience significant growth in the coming years, presenting opportunities for companies like Dakshidin to establish a presence in the region. Geographic expansion could involve establishing new cultivation facilities, distribution centers, or retail outlets. Timeline: 2-3 years.
- Online Sales Growth: Dakshidin can focus on growing its online sales channel through targeted marketing campaigns, enhanced website functionality, and improved customer service. The e-commerce market for CBD products is experiencing rapid growth, driven by increasing consumer adoption of online shopping and the convenience of purchasing CBD products from home. Investing in digital marketing and e-commerce infrastructure can help Dakshidin capture a larger share of the online CBD market. Timeline: Ongoing.
- Research and Development: Dakshidin can invest in research and development to develop innovative cannabis-based medical products and therapies. This could involve conducting clinical trials to evaluate the efficacy and safety of its products, as well as collaborating with research institutions to explore new applications for cannabis and CBD. Investing in R&D can help Dakshidin differentiate its products and establish a competitive advantage in the market. Timeline: Ongoing.
What Opportunities Does DKSC Have?
- Expansion into new geographic markets.
- Development of innovative cannabis-based medical products.
- Strategic partnerships with established companies.
- Growth of the online CBD market.
What Threats Does DKSC Face?
- Intense competition from other CBD/cannabis companies.
- Changing regulations and legal restrictions.
- Fluctuations in cannabis prices and demand.
- Potential for negative publicity and consumer perception.
What Are DKSC's Competitive Advantages?
- Established online sales portal for CBD products.
- Management of distribution channels across multiple market segments.
- Cultivation capabilities providing control over supply chain.
- Early mover advantage in the CBD/cannabis market (founded in 2007).
What Does DKSC Do?
Dakshidin Corporation, Inc., formerly known as Avrada, Inc. until February 2007, operates as a CBD/cannabis-based medical product company. The company cultivates cannabis and manages an online sales portal for its CBD products, catering to the growing market for cannabis-derived health and wellness solutions. Dakshidin manages distribution channel programs across various market segments, including retail distribution, reselling, and direct sales, indicating a multi-faceted approach to market penetration. Headquartered in Miami, Florida, with additional offices in Las Vegas, Nevada, Dakshidin aims to establish a presence in key geographic markets. The company's focus on CBD and cannabis-based medical products positions it within a rapidly evolving sector, driven by increasing acceptance and legalization of cannabis for medical and recreational use in various jurisdictions. Dakshidin's business model encompasses cultivation, online retail, and distribution partnerships, reflecting an integrated approach to the cannabis value chain. The company seeks to capitalize on the expanding demand for CBD products, which are marketed for a range of health and wellness applications.
What Products and Services Does DKSC Offer?
- Cultivates cannabis for medical product development.
- Operates an online sales portal for CBD products.
- Manages distribution channel programs in the retail market.
- Manages distribution channel programs in the reselling market.
- Manages distribution channel programs in the direct sales market.
- Develops and markets CBD/cannabis-based medical products.
How Does DKSC Make Money?
- Cultivation of cannabis to produce raw materials.
- Online retail sales of CBD products directly to consumers.
- Distribution agreements with retailers and resellers.
- Direct sales through various channels.
What Industry Does DKSC Operate In?
Dakshidin Corporation, Inc. operates within the rapidly expanding CBD and cannabis-based medical product industry. This sector is characterized by evolving regulations, increasing consumer acceptance, and growing demand for cannabis-derived health and wellness products. The competitive landscape includes both established pharmaceutical companies exploring cannabis-based therapies and numerous smaller players focused on specific niches within the market. Dakshidin's success depends on its ability to navigate the regulatory environment, differentiate its products, and effectively compete with other companies such as ERBB, FITX, FTEG, GEATF, and GRCU.
Who Are DKSC's Key Customers?
- Individual consumers seeking CBD products for health and wellness.
- Retail stores that sell CBD products.
- Resellers who distribute CBD products to various markets.
- Patients seeking cannabis-based medical products (where legally permissible).
F-Score 2/9Financial Health
Dakshidin Corporation, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.00 places it in the distress zone, a signal of elevated financial risk.
DKSC Valuation & Market Position
With a $1.77M market cap, Dakshidin Corporation, Inc. sits in the micro-cap segment of the market. Relative to its peer group, DKSC's quantitative score of 50/100 is below the peer average of 66/100.
ROE 0%Key Financial Metrics
Return on equity for Dakshidin Corporation, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -2.3%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Dakshidin Corporation, Inc. operates in the Industrial - Machinery industry within the Industrials sector. It is headquartered in Miami, US. The company is led by CEO Christopher Robin Haigh. DKSC has traded publicly since 2009.
DKSC Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see long-term value, potentially signaling confidence in DKSC's future prospects.
- Community sentiment indicates growing optimism around DKSC's strategic partnerships and their potential to unlock new market opportunities.
- Bullish voices highlight DKSC's innovative approach to problem-solving within their sector, fostering belief in sustained competitive advantage.
- Market perception is shifting positively as DKSC successfully navigates recent industry challenges, reinforcing investor confidence.
Bear Case
- Recent insider selling, while not always indicative of negative sentiment, could raise concerns about short-term prospects for DKSC.
- Community sentiment reveals worries regarding increased competition and its potential impact on DKSC's market share and profitability.
- Bearish views point to DKSC's reliance on a few key clients, creating vulnerability if those relationships falter.
- Market perception is cautious due to recent regulatory changes impacting DKSC's sector, potentially creating headwinds for future growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DKSC Latest News
No recent news available for DKSC.
DKSC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DKSC.
Price Targets
Wall Street price target analysis for DKSC.
DKSC MoonshotScore
What does this score mean?
The MoonshotScore rates DKSC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher Robin Haigh
CEO
Christopher Robin Haigh serves as the CEO of Dakshidin Corporation, Inc. Information regarding his detailed career history, educational background, and previous roles is not available in the provided data. Therefore, a comprehensive profile of his professional background cannot be constructed at this time. Further research would be required to ascertain his specific qualifications and experience in the healthcare or cannabis industries.
Track Record: Due to the limited information available, it is not possible to assess Christopher Robin Haigh's track record at Dakshidin Corporation, Inc. or in previous roles. Key achievements, strategic decisions, and company milestones under his leadership cannot be determined based on the provided data. Further information is needed to evaluate his performance and contributions to the company.
DKSC OTC Market Information
The OTC Other tier, also known as the Pink Sheets, represents the lowest tier of the OTC market. Companies in this tier often have limited or no reporting requirements, making it difficult for investors to obtain reliable information. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to stringent listing standards or regulatory oversight. This lack of regulation can lead to increased risks for investors, including potential fraud and manipulation. Companies in this tier may be distressed, early-stage, or have chosen not to meet the requirements for higher tiers.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial reporting requirements.
- Potential for fraud and manipulation.
- Low trading volume and illiquidity.
- Lack of regulatory oversight.
- Higher risk of company failure.
- Verify the company's legal standing and registration.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's potential for future growth and profitability.
- Understand the risks associated with investing in OTC Other companies.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 2007.
- Operates in the growing CBD/cannabis market.
- Manages distribution channels across multiple market segments.
- Headquartered in Miami, Florida, with offices in Las Vegas, Nevada.
Dakshidin Corporation, Inc. Healthcare Stock: Key Questions Answered
What does Dakshidin Corporation, Inc. do?
Dakshidin Corporation, Inc. operates as a CBD/cannabis-based medical product company. Its core activities include cultivating cannabis, managing an online sales portal for CBD products, and overseeing distribution channel programs across retail, reselling, and direct sales markets. The company focuses on developing and marketing cannabis-derived products for health and wellness applications, aiming to capitalize on the growing demand for CBD and related products.
What do analysts say about DKSC stock?
There is currently no available analyst coverage or consensus on Dakshidin Corporation, Inc. (DKSC) stock. This lack of coverage may be due to the company's OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before making any investment decisions, considering the limited information available and the risks associated with investing in OTC stocks.
What are the main risks for DKSC?
Dakshidin Corporation, Inc. faces several risks inherent to the CBD/cannabis industry, including evolving regulations, intense competition, and fluctuating market demand. As an OTC-listed company with an unknown disclosure status, DKSC also carries additional risks related to transparency, liquidity, and potential for fraud. The negative P/E ratio of -145.24 indicates a lack of profitability, which further increases the financial risk for investors. Investors should carefully consider these factors before investing.
What are the key factors to evaluate for DKSC?
Dakshidin Corporation, Inc. (DKSC) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does DKSC data refresh on this page?
DKSC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DKSC's recent stock price performance?
Dakshidin Corporation, Inc. (DKSC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the CBD/cannabis market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DKSC overvalued or undervalued right now?
Valuing Dakshidin Corporation, Inc. (DKSC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DKSC?
Before investing in Dakshidin Corporation, Inc. (DKSC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for Dakshidin Corporation, Inc.
- OTC market stocks carry higher risk than exchange-listed stocks.
- AI analysis pending for DKSC.